Despite the obesity-dependent effects of cilostazol on PCSK9 expression, we observed similar effects on the expression of AMPKα and PPARγ, suggesting that mechanisms beyond AMPK/PPARγ activation may be at play. The gene discussed is PCSK9; the disease is obesity due to melanocortin 4 receptor deficiency.